According to an update released by analysts at N 1 Singer the broker has now set a ‘Buy’ rating on shares of Reneuron Group (LON:RENE) with a price target of 9.
N 1 Singer on Friday reiterated Reneuron Group’s analyst rating as ‘Buy’ with its price target of 9 highlighting a potential increase of 293.01% from Reneuron Group’s current price of 2.29.
Over the last twelve months Reneuron Group’s stock price has decreased from 3.13 to 2.29, a change of -26.84%.
Reneuron Group has 3,164,618,000 shares in issue which have a share price of 2.29 giving Reneuron Group a market capitalisation of 72.47M GBp.
The company has a 50 day moving average of 2.36 and a 200 day moving average of 2.54. The 52 week high shares of Reneuron Group have reached is 3.71 whilst the 52 week low for the company’s shares is 2.
ReNeuron Group plc is a clinical-stage company. The Company, through its subsidiaries, is engaged in researching and developing cell-based therapies. The Company’s products are allogeneic. Its CTX stem cell therapy is used for the treatment of patients left disabled by the effects of a stroke. Its human retinal progenitor cells (hRPC) stem cell candidate is used for the treatment of retinitis pigmentosa (RP). Its second CTX stem cell candidate is for the treatment of critical limb ischaemia. The Company’s exosomes nanomedicine platform focuses on generating early pre-clinical data in cancer. Its ReNcell Products include ReNcellVM and ReNcellCX cell lines. It is engaged in Phase II clinical trial of CTX cells for stroke disability. It is engaged in Phase I clinical trial of CTX cells for Critical Limb Ischaemia. It is engaged in Phase I clinical trial of hRPC stem cell candidate. The Company has completed pre-clinical trials CTX-derived exosomes.